FDA grant Breakthrough Therapy Designation for teclistamab for relapsed or refractory multiple myeloma

Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors. Breakthrough designation is supported by data from the Phase 1 MajesTEC-1 study investigating use in refractory disease.

Source:

Biospace Inc.